The Injecto Polymers IPO is a closed SME Bookbuilding offer (Fresh capital only) that opened on 11 September 2026. The Injecto Polymers IPO closed on 16 September 2026, with an issue price of ₹100 per share. The Injecto Polymers IPO has a face value of ₹10 and a lot size of 1,200 shares. The Injecto Polymers IPO size aggregates up to ₹56 crore, listing on BSE SME on 21 September 2026. The Injecto Polymers IPO allotment was scheduled for 17 September 2026.
On the financial front, the Injecto Polymers IPO reported revenue of ₹376 crore for 31 Mar 2026, compared with ₹262 crore for 31 Mar 2025. The Injecto Polymers IPO PAT was ₹16 crore against ₹8 crore. The Injecto Polymers IPO EBITDA stood at ₹38 crore with a 10.13% margin. The Injecto Polymers IPO net worth as of 31 Mar 2026 was ₹63 crore.
Always verify The Injecto Polymers IPO details and GMP data with the official offer document before investing in the Injecto Polymers IPO.
Financial Summary
Amount in ₹ Crore
Metric
31 Mar 2026
31 Mar 2025
31 Mar 2024
Total Assets
271
171
121
Revenue
376
262
110
PAT
16
8
4
EBITDA
38
23
12
Net Worth
63
47
21
Reserves
48
32
8
Total Borrowing
165
101
83
Injecto Polymers IPO Financials FAQs
Revenue of Injecto Polymers (Amount in ₹ Crore) — 31 Mar 2026: 376; 31 Mar 2025: 262; 31 Mar 2024: 110. Profit after tax (PAT) — 31 Mar 2026: 16; 31 Mar 2025: 8; 31 Mar 2024: 4.
EBITDA of Injecto Polymers (Amount in ₹ Crore) — 31 Mar 2026: 38; 31 Mar 2025: 23; 31 Mar 2024: 12. The EBITDA margin is 10.13%.
Total assets — 31 Mar 2026: 271; 31 Mar 2025: 171; 31 Mar 2024: 121. Net worth — 31 Mar 2026: 63; 31 Mar 2025: 47; 31 Mar 2024: 21. Reserves & surplus — 31 Mar 2026: 48; 31 Mar 2025: 32; 31 Mar 2024: 8. (Amount in ₹ Crore)
Total borrowing of Injecto Polymers (Amount in ₹ Crore) — 31 Mar 2026: 165; 31 Mar 2025: 101; 31 Mar 2024: 83. Debt-to-equity ratio: 2.61.
The financials shown for Injecto Polymers IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.
